Enzychem Lifesciences Corp

183490

Company Profile

  • Business description

    Enzychem Lifesciences Corp develops and produces APIs and functional health foods. The company's business divisions are divided into the Global New Drug Development, Pharmaceutical Active Ingredients, and Health Functional Foods divisions, as well as the Bio-oil (HVO raw materials, SAF raw materials) business division of its subsidiary. The products of the company include erdosteine (cough suppressant/expectorant), gadobutrol (contrast agent), D-cycloserine (anti-tuberculosis agent), sarpogrelate (anticoagulant), zinc carnosine (anti-ulcer agent), and zaltoprofen (anti-inflammatory analgesic), and others.

  • Contact

    59, Biovalley-ro
    Wangam-dong
    Jecheon-siChungcheongbuk-do135-280
    KOR

    T: +82 436522845

    https://www.enzychem.co.kr

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    130

Stocks News & Analysis

stocks

ASX healthcare share remains undervalued ahead of earnings

Margin recovery remains the key driver for this ASX healthcare share.
stocks

Alphabet earnings: Strong AI monetization continues to spearhead results

We maintain our fair value estimate for wide-moat Alphabet.
stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,968.006.20-0.07%
CAC 408,299.09138.80-1.64%
DAX 4024,763.12392.29-1.56%
Dow JONES (US)51,711.65506.93-0.97%
FTSE 10010,639.1777.80-0.73%
HKSE25,210.81318.151.28%
NASDAQ25,137.69553.21-2.15%
Nikkei 22564,787.621,634.98-2.46%
NZX 50 Index13,741.8553.46-0.39%
S&P 5007,408.3090.66-1.21%
S&P/ASX 2008,795.000.70-0.01%
SSE Composite Index3,876.210.57-0.01%

Market Movers